Corona Virus Treatment and Prevention with Vitamin D
College of Medicine scientists and clinicians, led by world-renowned vitamin D research experts Bruce Hollis, Ph.D., professor emeritus in the Department of Pediatrics, and Carol Wagner, M.D., a professor in the Department of Pediatrics and neonatologist, are planning a focused research effort to determine if individuals with sufficient baseline levels of vitamin D have more protection against severe COVID-19 infection.
Recent reports in the medical literature point toward a potential link between vitamin D deficiency and the pathogenesis of COVID-19 in certain patients. This information aligns with what Hollis, Wagner and other national experts have established in their own vitamin D research in at-risk populations - unrelated to COVID-19 - that vitamin D deficiency is more prevalent among African Americans and individuals with more melanin in their skin as well as in some elderly nursing home residents who have very low exposure to sunlight. In addition, effective vitamin D repletion can be accomplished safely and with minimal expense.
“Our team has the ability to determine vitamin D levels for COVID-19-positive patients and track that information to begin this work. This area of study is worthy of their expertise and efforts,” said David J. Cole, M.D., FACS, MUSC president. “This is a great opportunity to raise awareness that this due diligence is needed so we can potentially help particularly vulnerable populations in our community.”
To be clear, neither these studies nor MUSC are suggesting that vitamin D cures or prevents COVID-19 infection. However, the body of prior and emerging scientific evidence would suggest that individuals with low vitamin D levels who contract COVID-19, including African Americans and elderly nursing home residents, might experience worse clinical outcomes than other groups with normal vitamin D levels.
“It is important to study this topic to determine if recommending vitamin D supplementation for vulnerable populations can make a difference in COVID-19 outcomes. If valid,” Cole explained, “we would have an inexpensive, readily available strategy not only to help these groups of individuals but also the general population of South Carolina and beyond.”
MUSC scientists point out that recent COVID-19 and vitamin D studies suggest that at-risk individuals with historically low levels of vitamin D also had increased severity of COVID-19 infection and worse clinical outcomes.
Hollis, Wagner and their team are rapidly pursuing clinical studies to validate or refute the clinical assumption that when patients have sufficient vitamin D levels, their immune responses to the virus’ primary targets are enabled, stronger and more capable of fighting off the most acute form of COVID-19.
As the research effort matures, Hollis and Wagner plan to offer guidance on whether supplementation in certain individuals improves their clinical outcomes following a positive COVID-19 test. In addition, they hope to offer insight into whether vitamin D supplementation for all South Carolinians could improve their vitamin D statuses and mitigate the severity of COVID19 should they become infected.
“Our previous work has demonstrated that African Americans and other vulnerable populations can achieve vitamin D sufficiency through clinically validated supplements, which is a relatively inexpensive therapy that has a large safety profile when given in doses between 4,000 to 6,000 international units a day to adults,” Hollis said. “Some individuals with low levels of melanin in their skin can achieve better vitamin D sufficiency just by standing or sitting for 15 to 20 minutes in the direct sunlight each day that its possible, which is another easy way to address low vitamin D levels.”
Additionally, vitamin D has been shown to play an important role in a number of other bodily processes like modulation of cell growth and differentiation and enabling proper innate and adaptive immune functions to fight off pathogens. It’s also thought to protect against some chronic conditions, including cardiovascular disease, diabetes and some cancers.
Hollis and Wagner have more than 60 years of combined vitamin D research experience, with a collective body of work referenced and replicated across the spectrum by institutions such as Harvard University and the National Institutes of Health. They have accrued thousands of citations and have been published in numerous peer-reviewed journals on various subtopics around vitamin D deficiency and sufficiency.